Table 1 Demographics characteristics and biochemical profiles of study subjects.

From: Plasma catecholamine metabolites are associated with disease activity and pathophysiological features in systemic lupus erythematosus using targeted LC–MS/MS

 

Healthy

SLE

P-value

Control

Inactive

Active

 

n

64

41

47

 

Age, year

44(34,58.25)

34.5(21.25,52) *

35(31,52) *

0.013

Sex, male%

23.4

17.1

12.7

0.357

ESR (mm/h)

NA

15.0(9.0,46.0)

35.5(14.0,61.0) ###

<0.001

CRP (mg/L)

NA

7.5(0.35,10.34)

4.37(0.92,21.37)

0.157

C3 (g/L)

NA

0.90 ± 0.046

0.63 ± 0.039 ###

<0.001

C4 (g/L)

NA

0.17(0.04,0.31)

0.09(0.05,0.13) ###

<0.001

IgG (g/L)

NA

10.10(6.60,14.95)

11.47(5.59,19.46)

0.357

SLEDAI Score

NA

1.0(0.0,2.0)

12.0(8.0,16.0)

<0.001

Anti-dsDNA positive (%)

NA

13.16

66.67

<0.001

Anti-Sm positive (%)

NA

24.32

39.02

0.199

ALT (IU/L)

13.18 (11.42,17.55)

11.08(7.21,15.56)

10.70(8.36,17.90)

0.893

AST (IU/L)

17.08(14.51,20.0)

13.95(12.16,20.1)

15.8(11.38,19.80)

0.634

TP (IU/L)

69.65(65.41,72.65)

55.18(46.65,66.65)*

47.4(25.76,58.0)***

###

<0.001

ALB (IU/L)

42.38(40.55,43.65)

32.75(24.72,38.90)

25.30(21.90,28.70) ***###

<0.001

GLO (IU/L)

25.50(23.55, 29.50)

23.0(19.20,26.60)

23.0(19.26,28.90)

0.253

TBIL (µmol/L)

9.90(7.20,12.15)

5.86(3.53,7.00)***

4.30(3.52,5.30)***

<0.001

DBIL (µmol/L)

2.75(2.20,3.50)

2.26(0.92,2.60) **

1.05(0.70,1.50) ***

<0.001

TBA (µmol/L)

2.08(1.80,3.95)

2.20(1.12,3.35)

2.60(1.18,3.70)

0.474

Urea (mmol/l)

4.04(3.39,4.90)

4.20(3.65,5.92)

4.49(3.43,5.62) **

0.006

Cr (µmol/L)

46.65(40.51,54.40)

56.08(45.66,62.50)

42.85(38.40,50.90)

0.370

UA (µmol/L)

245.95(205.79,290.10)

240.25(198.73,345.55)

266.0(209.36,327.80)

0.167

TG (mmol/l)

0.86(0.65,1.19)

0.83(0.74,1.50)

1.12(0.93,1.52)

0.091

CHOL (mmol/l)

4.42(3.76,5.08)

3.67(2.88,4.10) *

3.10(2.63,4.14) **

0.005

HDL (mmol/l)

1.20(1.06,1.42)

0.78(0.60,1.11) **

0.81(0.52,1.04) ***

<0.001

LDL (mmol/l)

2.34(2.03,3.07)

2.20(1.67,2.52)

1.83(1.40,2.66)

0.072

  1. Data were presented as mean ± standard deviation for normally distributed variables and as median (Q1, Q3) for non-normally distributed variables. ESR, erythrocyte sedimentation rate; CRP, C-reactive protein; C3, complement 3; C4, complement 4; IgG, Immunoglobulin G; anti-dsDNA: Anti-double-stranded DNA antibodie; Anti-Sm: Anti-Sm antibodies ALT, alanine transaminase; AST, aspartate transaminase; TP, total protein; ALB, albumin; GLO, globular protein; TBIL, total bilirubin; DBIL, direct bilirubin; TBA, total bile acid; Cr, creatinine; UA, urine acid; TG, triglyceride; TC, total cholesterol; HDL, high-density lipoprotein; LDL, low-density lipoprotein. P-values in the last column were calculated using one-way ANOVA or the Kruskal–Wallis H test, as appropriate. Asterisks and hash symbols indicate significance in post hoc comparisons: *P < 0.05; **P < 0.01; ***P < 0.001 compared with the control group. #P < 0.05; ##P < 0.01; ###P < 0.001 compared with the SLE-inactive group.
Back to article page